ThromboGenics

ThromboGenics, Eleven to develop novel therapeutic for ophthalmic disease

Wednesday, May 29, 2013

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, has entered into a research collaboration and license agreement with ThromboGenics, an integrated biopharmaceutical company, to research and develop a protein therapeutic based on a novel biologic target implicated in ophthalmic disease.

[Read More]